Skip to main content

Mike Catelani, Chris Johnson, Robert Wicke, Patrick Carroll, Clive Seymour, Charles Montgomery, Russell Medford, John Mohr


Axon Instruments promoted three employees to newly created vice presidential positions last week: Mike Catelani has become vice president and CFO, Chris Johnson vice president for hardware engineering, and Robert Wicke vice president for software engineering.

Catelani had been Axon’s director of finance since 2002. Prior to joining the company, he was vice president of finance for Kirell Energy Systems. Catelani holds an MBA from the University of California, Davis, and a BSc in business administration/accountancy from California State University, Sacramento. Johnson was promoted from director of hardware engineering. Before joining Axon, he was director of product engineering at Silicon Valley Group. Johnson holds an MS in electrical engineering and engineering management from Santa Clara University and two BS degrees, in mechanical and electrical engineering, from the University of California, Davis.

Wicke was promoted from director of software engineering. He holds an MS in mathematical visualization from the University of Oregon and a BA in mathematics and computer science from Drew University.

Patrick Carroll has become chief business officer of BioTrove, the company said last week. He joins the company from Applied Biosystems, where he was senior vice president of worldwide sales. He holds MS and BA degrees in biological sciences from the University of Delaware and an MBA in marketing from Loyola College. BioTrove, of Woburn, Mass., develops nanofluidic biological assay platforms.

Clive Seymour has joined Bruker Daltonics, a unit of Bruker BioSciences, as vice president for Asia-Pacific, the company said last week. He joins Bruker from Biacore, where he was vice president for the Asia Pacific region.

Former Celera Genomics vice president of business development Charles Montgomery joins Atherogenics of Atlanta as vice president of business development, said the pharmaceutical company, which focuses on chronic inflammatory diseases. Montgomery will report directly to Russell Medford, president and chief executive officer of the company. Previously, Montgomery was vice president and co-head of business development and strategic planning at DuPont Pharmaceuticals. Montgomery holds a PhD in organic chemistry from the University of Minnesota, and a BS in chemistry from Southern Methodist University. He succeeds John Mohr, who has left Atherogenics to pursue other business opportunities

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.